Gilead completes CymaBay acquisition but negative impact on 2024 EPS (NASDAQ:GILD) Markets March 22, 2024 [ad_1] Sundry Images/iStock Editorial through Getty Photographs Gilead Sciences (NASDAQ:GILD) has accomplished its $4.3B acquisition of CymaBay Therapeutics (NASDAQ:CBAY). Nonetheless,…
